[The use of myelopid in the combined treatment of infectious-inflammatory complications in the postoperative period in neuro-oncology patients].
Clinical observations over 48 neurosurgical patients with infectious inflammatory complications and study of their immune status showed that a course of immunocorrective therapy with myelopid produces a favourable clinical effect and normalizes the patient's immune status. Myelopid causes the best normalizing effect in patients with nontumorous pathology of the central nervous system and in extracerebral neoplasms.
Lisianyĭ
N I
NI
Romodanov
S A
SA
Radzievskiĭ
A A
AA
Rudenko
V A
VA
Pedachenko
E G
EG
D028341:Activins; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000917:Antibody Formation / Q000187:drug effects; D001853:Bone Marrow / Q000276:immunology*; D003422:Critical Care; D004341:Drug Evaluation; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D009423:Nervous System Neoplasms / Q000188:drug therapy* / Q000276:immunology; D009842:Oligopeptides; D010455:Peptides / Q000627:therapeutic use*; D011182:Postoperative Care; D011183:Postoperative Complications / Q000188:drug therapy* / Q000276:immunology
D000276:Adjuvants, Immunologic; D009842:Oligopeptides; D010455:Peptides; C044147:activin B; D028341:Activins; C048617:myelopeptides
Primenenie mielopida v kompleksnom lechenii infektsionno-vospalitel'nykh oslozhneniĭ v posleoperatsionnom periode u neĭroonkologicheskikh bol'nykh.